FRANK SINGER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In the December 1984 issue, Holloway and colleagues (1) present a cost-effectiveness comparison of gentamicin and tobramycin. Referring to studies done at the Johns Hopkins Hospital, they state that "no patient has required either temporary or permanent dialysis because of aminoglycoside-induced nephrotoxicity," but they go on to calculate the incidence of permanent dialysis secondary to gentamicin toxicity necessary to equalize its cost with that of tobramycin. Their analysis indicates that 20% of patients they classify as severely nephrotoxic (1 out of every 50 patients with nephrotoxicity) would be required to have dialysis to equalize these costs.
SINGER F. Cost Effectiveness of Gentamicin and Tobramycin. Ann Intern Med. 1985;102:867–868. doi: https://doi.org/10.7326/0003-4819-102-6-867
Download citation file:
Published: Ann Intern Med. 1985;102(6):867-868.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use